PBH

Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.75 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prestige Consumer Healthcare Inc revenue for the last quarter amounts to 274.11M USD, decreased -3.41 % YoY.

Prestige Consumer Healthcare Inc. EPS for the last quarter amounts to 0.86 USD, decreased -21.10 % YoY.

Prestige Consumer Healthcare Inc (PBH) has 600 emplpoyees as of December 16 2025.

Today PBH has the market capitalization of 2.97B USD.